Clinical trial · Interventional
Oncology Care at Home for BMT and CAR-T
Design of a Patient-Centered Approach to Manage Bone Marrow Transplant Patients and CAR-T Cell Therapy in a Home Setting
NCT05826288CI-TRIAL-00086328completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the potential for successfully using technology-assisted in-home oncology care to provide improved care coordination and management, and appropriate referral to treatment for patients receiving bone marrow transplant (BMT) or chimeric antigen receptor (CAR) T-cell therapy (CAR-T). The technology-assisted in-home oncology care program includes remote patient monitoring (RPM), telemedicine, and home-based health care services.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BioIntelliSense BioButton Rechargable | Other | — | UNRESOLVED |
| Memora Health two-way patient engagement platform provided by RC | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Post BMT or CAR-T patients receiving care at UCHealth
- description
- Participants will be recruited for this study from among three discrete patient populations: * Allogeneic BMT patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the Anschutz Medical Campus (AMC) for at least 90 days post-transplant. * Autologous BMT patients receiving care at UCHealth who are planning to reside in the Denver metro Area within 45 minutes of the AMC for at least 30 days post-transplant. * CAR-T patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the AMC for at least 30 days post treatment.
- interventionNames
- Other: BioIntelliSense BioButton Rechargable
- Other: Memora Health two-way patient engagement platform provided by RC
Primary outcomes (12)
- measure
- Number of patients reporting symptoms
- timeFrame
- 90 Days
- description
- Determine the number of patients reporting symptoms via EPRO
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years to 89 years old * Bone marrow transplant recipients (allogeneic and autologous) or CAR-T patients * Determined by care provider to be stable for discharge to home setting for outpatient care according to clinical practice standard operating procedures (SOPs) * Residing in the Denver metro area for the duration of the study within 45 minutes of the AMC * Has in-home caregiver support 24/7 (i.e., does not live alone) * Has self-reported reliable telephone and home internet service and a stable wireless network * Patient agrees to not submerge the BioButton Rechargeable device in more than 3 feet of water or submerge for longer than 30 minutes at a time. * Patient owns or possesses, as the primary user with reliable daily access, a mobile device (iOS or Android) capable of running the study's mobile applications and accepting the terms and conditions * Patient has SMS texting capacity and an unlimited texting plan or other plan sufficient for study text messaging without undue patient burden * Patient is willing to complete and log a self-check of temperature twice daily and return the log to the study team at the end of the study * Patient is willing to be available for the duration of the study * Patient has access to reliable transportation to the hospital 24/7 Exclusion Criteria: * Patients will be excluded from study participation if the PI or designated care provider believes study participation would not be in the patient's best interest for clinical reasons. * Patients may also be excluded from study participation if in the opinion of the PI they have a medical condition that may impede their ability to adhere to the study protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.